Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALPG | P10696 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24177180 | 0.85 | HPGD (0.62) | POLBALPGHPGDPKMMEN1 | |
| SCHEMBL21941760 | 0.85 | HPGD (0.62) | POLBALPGHPGDPKMMEN1 | |
| SCHEMBL21880364 | 0.84 | HPGD (0.57) | POLBALPGHPGDALDH1A1HSD17B10 | |
| SCHEMBL29306572 | 0.84 | HPGD (0.57) | POLBALPGHPGDALDH1A1HSD17B10 | |
| SCHEMBL26127583 | 0.82 | POLB (0.52) | POLBALPGHPGDPKMMEN1 | |
| SCHEMBL26120640 | 0.82 | POLB (0.52) | POLBALPGHPGDPKMMEN1 | |
| SCHEMBL27806423 | 0.82 | POLB (0.52) | POLBALPGHPGDPKMMEN1 | |
| SCHEMBL6360835 | 0.81 | POLB (0.55) | POLBALPGHPGDPKMMEN1 | |
| SCHEMBL24177181 | 0.81 | POLB (0.55) | POLBALPGHPGDPKMMEN1 | |
| SCHEMBL29306396 | 0.81 | POLB (0.49) | POLBALPGHPGDPKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197380-A1 | PHARMACEUTICAL INTERMEDIATE AND SYNTHESIS METHOD, AND ISOQUINOLINE DERIVATIVE AND SYNTHESIS METHOD THEREFOR | BANGENTAI(SHANDONG) BIOSCIENCES GROUP SHARE CO., LTD. (CN) | 2025-06-19 | — | — | US | claimed |
| CN-114573506-B | Drug intermediate and synthetic method thereof, isoquinoline derivative and synthetic method thereof | 邦恩泰(山东)生物医药科技集团股份有限公司 | 2022-09-30 | — | — | CN | claimed |
| US-20250197380-A1 | PHARMACEUTICAL INTERMEDIATE AND SYNTHESIS METHOD, AND ISOQUINOLINE DERIVATIVE AND SYNTHESIS METHOD THEREFOR | BANGENTAI(SHANDONG) BIOSCIENCES GROUP SHARE CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| CN-113801069-B | Alfuzosin hydrochloride intermediate compound | 鲁南制药集团股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023185027-A1 | PREPARATION METHOD FOR ISOQUINOLINE COMPOUND | 邦恩泰(山东)生物医药科技集团股份有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023179068-A1 | DRUG INTERMEDIATE AND SYNTHETIC METHOD, AND ISOQUINOLINE DERIVATIVE AND SYNTHETIC METHOD THEREFOR | 邦恩泰(山东)生物医药科技集团股份有限公司 | 2023-09-28 | — | — | WO | disclosed |
| WO-2023179068-A1 | DRUG INTERMEDIATE AND SYNTHETIC METHOD, AND ISOQUINOLINE DERIVATIVE AND SYNTHETIC METHOD THEREFOR | 邦恩泰(山东)生物医药科技集团股份有限公司 | 2023-09-28 | — | — | WO | disclosed |
| CN-114573506-B | Drug intermediate and synthetic method thereof, isoquinoline derivative and synthetic method thereof | 邦恩泰(山东)生物医药科技集团股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-114591273-A | Synthesis method and application of N-methyl-N' -tetrahydrofuran formyl propane diamine oxalate | 邦恩泰(山东)生物医药科技集团股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114573569-A | Preparation method of isoquinoline compounds | 邦恩泰(山东)生物医药科技集团股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-114573506-A | Drug intermediate and synthetic method thereof, isoquinoline derivative and synthetic method thereof | 邦恩泰(山东)生物医药科技集团股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2008021891-A2 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021891-A2 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| WO-2008015525-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF ALFUZOSIN HYDROCHLORIDE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2008-02-07 | — | — | WO | disclosed |
| WO-2007063556-A2 | AN IMPROVED AND INDUSTRIAL PROCESS FOR THE PREPARATION OF ALFUZOSIN HYDROCHLORIDE AND ITS NOVEL POLYMORPHS | MSN LABORATORIES LIMITED (IN) | 2007-06-07 | — | — | WO | disclosed |
| US-20070066824-A1 | PREPARATION OF ALFUZOSIN | DR. REDDY'S LABORATORIES, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070066824-A1 | PREPARATION OF ALFUZOSIN | DR. REDDY'S LABORATORIES, INC. | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | ADRB1, ADRB2, ADRB3 | POLB 2328/4885ALPG 2088/4885HPGD 148/4885 |
| US-20250197380-A1 | PHARMACEUTICAL INTERMEDIATE AND SYNTHESIS METHOD, AND ISOQUINOLINE DERIVATIVE AND SYNTHESIS METHOD THEREFOR | PARK7, SQLE, CYP4F11 | POLB 961/4885ALPG 4804/4885HPGD 133/4885 |
| US-20070066824-A1 | PREPARATION OF ALFUZOSIN | MAP7, LPXN, QDPR | POLB 4616/4885ALPG 4024/4885HPGD 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.